BioRestorative (BRTX) Completes Phase 2 Dosing for BRTX-100, Shares Surge 20%

BioRestorative Therapies Inc. (BRTX) completed dosing in its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease, the company said on May 27, 2026, triggering a 20% rally in its shares. The trial is evaluating the safety and preliminary efficacy of the autologous stem cell-based therapy in patients with degenerative disc conditions. Completion of enrollment and dosing represents a key milestone, though topline data have not been released. BRTX-100 aims to provide a non-surgical alternative for treating lumbar disc disease, a condition affecting millions of adults. The stock’s jump reflects investor optimism about the program’s progress and its potential for accelerated regulatory pathways.